Vaccines

Latest News


Video Series


Latest Videos


Shorts

Hepatitis B’s Hidden Household Risk for Infants
1:11
Hepatitis B’s Hidden Household Risk for Infants
a day ago
by
Karen B. Jacobson, MD, MPH(+1 more)
Why the Hepatitis B Birth Dose Is the Most Feasible Protection
0:33
Why the Hepatitis B Birth Dose Is the Most Feasible Protection
2 days ago
by
Karen B. Jacobson, MD, MPH(+1 more)
Why People Put Off Vaccines—and How to Help Them Act
1:32
Why People Put Off Vaccines—and How to Help Them Act
2 days ago
by
Robert H. Hopkins Jr. MD(+1 more)
When Herd Immunity Fails: How Falling Vaccination Rates Endanger Vulnerable Children
0:47
When Herd Immunity Fails: How Falling Vaccination Rates Endanger Vulnerable Children
24 days ago
by
Sharon Nachman, MD(+1 more)
Why Are Vaccine Rates Falling in the US?
1:01
Why Are Vaccine Rates Falling in the US?
2 months ago
by
Robert H. Hopkins Jr. MD(+1 more)
Physician Warns Kennedy Vaccine Task Force Is Poised to Undermine Immunization Schedule
0:47
Physician Warns Kennedy Vaccine Task Force Is Poised to Undermine Immunization Schedule
2 months ago
by
Jason Goldman, MD, MACP(+1 more)
Executive Orders vs Evidence: Why Vaccine Policy Must Follow the Science
1:11
Executive Orders vs Evidence: Why Vaccine Policy Must Follow the Science
2 months ago
by
Jason Goldman, MD, MACP(+1 more)
How the ACIP Has Historically Operated
0:57
How the ACIP Has Historically Operated
7 months ago
by
Sharon Nachman, MD
What Has Happened to the ACIP in the Last Year?
0:59
What Has Happened to the ACIP in the Last Year?
7 months ago
by
Sharon Nachman, MD
Future Regulatory Reviews of COVID-19 Vaccines
0:45
Future Regulatory Reviews of COVID-19 Vaccines
7 months ago
by
Sharon Nachman, MD

Podcasts


CME Content


More News

With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.

FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax's partners, all reformulated to target the XFG variant, giving clinicians several options ahead of the fall respiratory virus season.

The Vaccine Integrity Project, in collaboration with the American Medical Association, conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season. JAMA published the review, and here is an overview of the data going into this year's seasonal respiratory virus season.

GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.

The FDA has approved formulations for the 2026-2027 vaccines including Pfizer-BioNTech's Comirnaty XFG, Novavax's commercial partners Sanofi and Takeda have secured approvals for its Nuvaxovid, and Moderna's Spikevax and mNEXSPIKE vaccines, all with protections against the currently circulating variant.

The FDA has approved Pfizer-BioNTech's 2026-2027 Comirnaty XFG formula, an updated COVID-19 vaccine targeting the XFG variant, for adults 65 and older and for individuals ages five through 64 with at least one high-risk underlying condition.

The US childhood vaccine schedule was the big news this month with the presidential executive order making changes to it as well as the latest Centers for Disease Control and Prevention kindergarten immunization numbers for the 2025-2026 year. Learn more about the news with clinician commentary and how it might impact patient care.